Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma

JAMA. 2023 Jul 31:10.1001/jama.2023.11846. doi: 10.1001/jama.2023.11846. Online ahead of print.
No abstract available

Plain language summary

This Viewpoint discusses the unfairness of current CAR T-cell therapy allocation practices and offers alternative methods to more fairly allocate therapy.